{"transactions":[{"id":767742,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T20:30:04.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":24122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":45122,"source":{"system":"sec-edgar","filing":"0001193125-26-234563","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000119312526234563/ownership.xml","form_type":"4"}},{"id":944269,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:17:53.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":21.31,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":11100},"source":{"system":"sec-edgar","filing":"0001378690-26-000003","document":"wk-form4_1767835069.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000137869026000003/wk-form4_1767835069.xml","form_type":"4"}},{"id":944268,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:17:53.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":22.81,"expiration_date":"2034-12-16","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001378690-26-000003","document":"wk-form4_1767835069.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000137869026000003/wk-form4_1767835069.xml","form_type":"4"}},{"id":944267,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:17:53.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":12.64,"expiration_date":"2034-07-17","underlying":"Common Stock","underlying_shares":2125},"source":{"system":"sec-edgar","filing":"0001378690-26-000003","document":"wk-form4_1767835069.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000137869026000003/wk-form4_1767835069.xml","form_type":"4"}},{"id":944266,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:17:53.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2125,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":23.4,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":2125},"source":{"system":"sec-edgar","filing":"0001378690-26-000003","document":"wk-form4_1767835069.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000137869026000003/wk-form4_1767835069.xml","form_type":"4"}},{"id":944265,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:17:53.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1400,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":10.6,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":1400},"source":{"system":"sec-edgar","filing":"0001378690-26-000003","document":"wk-form4_1767835069.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000137869026000003/wk-form4_1767835069.xml","form_type":"4"}},{"id":944264,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:17:53.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":875,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":38.4,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":875},"source":{"system":"sec-edgar","filing":"0001378690-26-000003","document":"wk-form4_1767835069.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000137869026000003/wk-form4_1767835069.xml","form_type":"4"}},{"id":944263,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:17:53.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":875,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":79.4,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":875},"source":{"system":"sec-edgar","filing":"0001378690-26-000003","document":"wk-form4_1767835069.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000137869026000003/wk-form4_1767835069.xml","form_type":"4"}},{"id":944262,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:17:53.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":550,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":32,"expiration_date":"2029-06-16","underlying":"Common Stock","underlying_shares":550},"source":{"system":"sec-edgar","filing":"0001378690-26-000003","document":"wk-form4_1767835069.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000137869026000003/wk-form4_1767835069.xml","form_type":"4"}},{"id":944261,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:17:53.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":550,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":106,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":550},"source":{"system":"sec-edgar","filing":"0001378690-26-000003","document":"wk-form4_1767835069.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000137869026000003/wk-form4_1767835069.xml","form_type":"4"}},{"id":944260,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:17:53.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":550,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":138,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":550},"source":{"system":"sec-edgar","filing":"0001378690-26-000003","document":"wk-form4_1767835069.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000137869026000003/wk-form4_1767835069.xml","form_type":"4"}},{"id":944259,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:17:53.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":450,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":204.4,"expiration_date":"2026-06-21","underlying":"Common Stock","underlying_shares":450},"source":{"system":"sec-edgar","filing":"0001378690-26-000003","document":"wk-form4_1767835069.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000137869026000003/wk-form4_1767835069.xml","form_type":"4"}},{"id":1106136,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-18T21:05:20.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":11100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) June 18, 2026 or (ii) the day prior to the date of the Issuer's 2026 annual meeting of stockholders."}],"balance_after":11100,"derivative":{"exercise_price":21.31,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":11100},"source":{"system":"sec-edgar","filing":"0001610618-25-000067","document":"wk-form4_1750280713.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000161061825000067/wk-form4_1750280713.xml","form_type":"4"}},{"id":1170926,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2025-04-16T21:44:03.000Z","date":"2025-04-16","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest with respect to one-third (1/3) of the shares of common stock on April 16, 2026, and will vest in substantially equal quarterly installments over the twenty-four (24) months thereafter, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates."}],"balance_after":35000,"derivative":{"exercise_price":4.23,"expiration_date":"2035-04-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000950170-25-054886","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000095017025054886/ownership.xml","form_type":"4"}},{"id":1170925,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-16T21:44:03.000Z","date":"2025-04-16","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on April 16, 2025. One-third (1/3) of the total number of RSUs granted vest on April 16, 2026, and will vest in substantially equal quarterly installments over the twenty-four (24) months thereafter, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":21000,"source":{"system":"sec-edgar","filing":"0000950170-25-054886","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000095017025054886/ownership.xml","form_type":"4"}},{"id":1325239,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-19T23:19:35.000Z","date":"2024-12-17","kind":"grant","planned":false,"acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of December 17, 2024."}],"balance_after":20500,"derivative":{"exercise_price":22.81,"expiration_date":"2034-12-16","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001610618-24-000154","document":"wk-form4_1734650368.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000161061824000154/wk-form4_1734650368.xml","form_type":"4"}},{"id":1451135,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-19T20:49:32.000Z","date":"2024-07-18","kind":"grant","planned":false,"acquired":true,"shares":2125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2025 annual meeting of stockholders."}],"balance_after":2125,"derivative":{"exercise_price":12.64,"expiration_date":"2034-07-17","underlying":"Common Stock","underlying_shares":2125},"source":{"system":"sec-edgar","filing":"0001610618-24-000098","document":"wk-form4_1721422165.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000161061824000098/wk-form4_1721422165.xml","form_type":"4"}},{"id":1845067,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T21:23:23.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":42500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2024 annual meeting of stockholders."}],"balance_after":42500,"derivative":{"exercise_price":1.17,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":42500},"source":{"system":"sec-edgar","filing":"0001610618-23-000069","document":"wf-form4_168755538288047.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000161061823000069/wf-form4_168755538288047.xml","form_type":"4"}},{"id":2040188,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-02-01T01:55:00.000Z","date":"2023-01-29","kind":"tax_withholding","acquired":false,"shares":431,"price":1.5,"value":646.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":11989,"source":{"system":"sec-edgar","filing":"0001104659-23-008854","document":"tm231658-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465923008854/tm231658-5_4seq1.xml","form_type":"4"}},{"id":2057427,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-10T22:56:53.000Z","date":"2023-01-06","kind":"tax_withholding","acquired":false,"shares":11,"price":1.3,"value":14.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":12420,"source":{"system":"sec-edgar","filing":"0001104659-23-002821","document":"tm231658-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465923002821/tm231658-4_4seq1.xml","form_type":"4"}},{"id":2066764,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-04T23:09:46.000Z","date":"2022-12-31","kind":"tax_withholding","acquired":false,"shares":5,"price":1.89,"value":9.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":12431,"source":{"system":"sec-edgar","filing":"0001104659-23-001008","document":"tm231658-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465923001008/tm231658-2_4seq1.xml","form_type":"4"}},{"id":2092122,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-12-08T21:34:08.000Z","date":"2022-12-06","kind":"tax_withholding","acquired":false,"shares":9,"price":2.02,"value":18.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":12436,"source":{"system":"sec-edgar","filing":"0001104659-22-125506","document":"tm2231811-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922125506/tm2231811-3_4seq1.xml","form_type":"4"}},{"id":2098034,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-12-02T22:15:38.000Z","date":"2022-11-30","kind":"tax_withholding","acquired":false,"shares":5,"price":2.25,"value":11.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":12445,"source":{"system":"sec-edgar","filing":"0001104659-22-124180","document":"tm2231811-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922124180/tm2231811-1_4seq1.xml","form_type":"4"}},{"id":2122146,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-11-08T22:24:19.000Z","date":"2022-11-06","kind":"tax_withholding","acquired":false,"shares":10,"price":2.2392,"value":22.392,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":12450,"source":{"system":"sec-edgar","filing":"0001104659-22-116022","document":"tm2229411-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922116022/tm2229411-3_4seq1.xml","form_type":"4"}},{"id":2128362,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-11-01T21:08:24.000Z","date":"2022-10-31","kind":"tax_withholding","acquired":false,"shares":5,"price":2.54,"value":12.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":12460,"source":{"system":"sec-edgar","filing":"0001104659-22-113574","document":"tm2229411-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922113574/tm2229411-2_4seq1.xml","form_type":"4"}},{"id":2139103,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-10-11T21:03:21.000Z","date":"2022-10-06","kind":"tax_withholding","acquired":false,"shares":9,"price":2.72,"value":24.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":12465,"source":{"system":"sec-edgar","filing":"0001104659-22-107772","document":"tm2227851-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922107772/tm2227851-2_4seq1.xml","form_type":"4"}},{"id":2144196,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-10-05T01:31:52.000Z","date":"2022-09-30","kind":"tax_withholding","acquired":false,"shares":5,"price":2.08,"value":10.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of ordinary shares reported on this Form 4 reflects a 1-for-25 reverse stock split effected on September 15, 2022."}],"balance_after":12474,"source":{"system":"sec-edgar","filing":"0001104659-22-106053","document":"tm2227483-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922106053/tm2227483-2_4seq1.xml","form_type":"4"}},{"id":2164077,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-07T22:00:07.000Z","date":"2022-09-06","kind":"tax_withholding","acquired":false,"shares":225,"price":0.1566,"value":35.235,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":311977,"source":{"system":"sec-edgar","filing":"0001104659-22-098289","document":"tm2224984-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922098289/tm2224984-3_4seq1.xml","form_type":"4"}},{"id":2168866,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-01T22:38:24.000Z","date":"2022-08-31","kind":"tax_withholding","acquired":false,"shares":107,"price":0.1646,"value":17.6122,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":312202,"source":{"system":"sec-edgar","filing":"0001104659-22-097114","document":"tm2224984-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922097114/tm2224984-2_4seq1.xml","form_type":"4"}},{"id":2185503,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Phantom Shares","published_at":"2022-08-16T00:50:40.000Z","date":"2022-08-11","kind":"exercise","acquired":true,"shares":119900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( \"Phantom Shares\"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares."},{"field":"date","element":"transactionDate","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( \"Phantom Shares\"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( \"Phantom Shares\"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( \"Phantom Shares\"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares."}],"balance_after":119900,"derivative":{"underlying":"Ordinary Shares","underlying_shares":119900},"source":{"system":"sec-edgar","filing":"0001104659-22-091492","document":"tm2222534-20_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922091492/tm2222534-20_4seq1.xml","form_type":"4"}},{"id":2185502,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Appreciation Right","published_at":"2022-08-16T00:50:40.000Z","date":"2022-08-11","kind":"exercise","acquired":true,"shares":239800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the \"2022 AGM\") of Nabriva Therapeutics plc (the \"Issuer\"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the \"2022 AGM\") of Nabriva Therapeutics plc (the \"Issuer\"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continued employment with the Issuer, the cash-settled share appreciation right will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the cash-settled share appreciation right will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the cash-settled share appreciation right will vest on a monthly pro-rata basis over the remaining vesting period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the \"2022 AGM\") of Nabriva Therapeutics plc (the \"Issuer\"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the \"2022 AGM\") of Nabriva Therapeutics plc (the \"Issuer\"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right."}],"balance_after":239800,"derivative":{"exercise_price":0.45,"expiration_date":"2032-01-27","underlying":"Ordinary Shares","underlying_shares":239800},"source":{"system":"sec-edgar","filing":"0001104659-22-091492","document":"tm2222534-20_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922091492/tm2222534-20_4seq1.xml","form_type":"4"}},{"id":2185501,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-08-16T00:50:40.000Z","date":"2022-08-11","kind":"exercise","acquired":false,"shares":119900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( \"Phantom Shares\"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares."},{"field":"date","element":"transactionDate","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( \"Phantom Shares\"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( \"Phantom Shares\"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( \"Phantom Shares\"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":119900},"source":{"system":"sec-edgar","filing":"0001104659-22-091492","document":"tm2222534-20_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922091492/tm2222534-20_4seq1.xml","form_type":"4"}},{"id":2185500,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Options","published_at":"2022-08-16T00:50:40.000Z","date":"2022-08-11","kind":"exercise","acquired":false,"shares":239800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the \"2022 AGM\") of Nabriva Therapeutics plc (the \"Issuer\"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the \"2022 AGM\") of Nabriva Therapeutics plc (the \"Issuer\"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continued employment with the Issuer, the cash-settled share appreciation right will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the cash-settled share appreciation right will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the cash-settled share appreciation right will vest on a monthly pro-rata basis over the remaining vesting period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the \"2022 AGM\") of Nabriva Therapeutics plc (the \"Issuer\"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the \"2022 AGM\") of Nabriva Therapeutics plc (the \"Issuer\"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right."}],"balance_after":0,"derivative":{"exercise_price":0.45,"expiration_date":"2032-01-27","underlying":"Ordinary Shares","underlying_shares":239800},"source":{"system":"sec-edgar","filing":"0001104659-22-091492","document":"tm2222534-20_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922091492/tm2222534-20_4seq1.xml","form_type":"4"}},{"id":2191843,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-08-08T21:44:11.000Z","date":"2022-08-06","kind":"tax_withholding","acquired":false,"shares":225,"price":0.1847,"value":41.5575,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":312309,"source":{"system":"sec-edgar","filing":"0001104659-22-087403","document":"tm2222534-14_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922087403/tm2222534-14_4seq1.xml","form_type":"4"}},{"id":2195537,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-08-04T01:45:09.000Z","date":"2022-07-31","kind":"tax_withholding","acquired":false,"shares":107,"price":0.179,"value":19.153,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":312534,"source":{"system":"sec-edgar","filing":"0001104659-22-085786","document":"tm2222534-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922085786/tm2222534-2_4seq1.xml","form_type":"4"}},{"id":2210672,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-07-07T20:11:15.000Z","date":"2022-07-06","kind":"tax_withholding","acquired":false,"shares":225,"price":0.1822,"value":40.995,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":312641,"source":{"system":"sec-edgar","filing":"0001104659-22-078028","document":"tm2220272-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922078028/tm2220272-4_4seq1.xml","form_type":"4"}},{"id":2217060,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-07-01T22:08:12.000Z","date":"2022-06-30","kind":"tax_withholding","acquired":false,"shares":107,"price":0.182,"value":19.474,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":312866,"source":{"system":"sec-edgar","filing":"0001104659-22-076941","document":"tm2220272-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922076941/tm2220272-2_4seq1.xml","form_type":"4"}},{"id":2221913,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T21:25:22.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2023 annual meeting of stockholders."}],"balance_after":28000,"derivative":{"exercise_price":0.53,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001610618-22-000054","document":"wf-form4_165610589357308.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000161061822000054/wf-form4_165610589357308.xml","form_type":"4"}},{"id":2223048,"issuer":{"id":116495,"kind":"organization","name":"OTONOMY, INC.","symbol":"OTIC"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-23T16:35:16.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date."}],"balance_after":27500,"derivative":{"exercise_price":1.95,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0001209191-22-038892","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493566/000120919122038892/doc4.xml","form_type":"4"}},{"id":2240052,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-06-07T20:47:48.000Z","date":"2022-06-06","kind":"tax_withholding","acquired":false,"shares":225,"price":0.2,"value":45.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":312973,"source":{"system":"sec-edgar","filing":"0001104659-22-068985","document":"tm2217481-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922068985/tm2217481-4_4seq1.xml","form_type":"4"}},{"id":2247259,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-06-02T20:10:42.000Z","date":"2022-05-31","kind":"tax_withholding","acquired":false,"shares":107,"price":0.2066,"value":22.1062,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":313198,"source":{"system":"sec-edgar","filing":"0001104659-22-067620","document":"tm2217481-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922067620/tm2217481-2_4seq1.xml","form_type":"4"}},{"id":2277485,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-05-09T22:32:31.000Z","date":"2022-05-06","kind":"tax_withholding","acquired":false,"shares":225,"price":0.26,"value":58.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":313305,"source":{"system":"sec-edgar","filing":"0001104659-22-057688","document":"tm2214926d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922057688/tm2214926d1_4seq1.xml","form_type":"4"}},{"id":2284032,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-05-03T20:59:45.000Z","date":"2022-04-30","kind":"tax_withholding","acquired":false,"shares":107,"price":0.31,"value":33.17,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":313530,"source":{"system":"sec-edgar","filing":"0001104659-22-055332","document":"tm2211509-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922055332/tm2211509-6_4seq1.xml","form_type":"4"}},{"id":2300156,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-04-08T20:16:27.000Z","date":"2022-04-06","kind":"tax_withholding","acquired":false,"shares":219,"price":0.41,"value":89.79,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":313637,"source":{"system":"sec-edgar","filing":"0001104659-22-044220","document":"tm2211509-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922044220/tm2211509-4_4seq1.xml","form_type":"4"}},{"id":2307850,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-04-04T22:27:21.000Z","date":"2022-03-31","kind":"tax_withholding","acquired":false,"shares":104,"price":0.42,"value":43.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":313856,"source":{"system":"sec-edgar","filing":"0001104659-22-042376","document":"tm2211509-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922042376/tm2211509-2_4seq1.xml","form_type":"4"}},{"id":2344205,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-08T21:12:43.000Z","date":"2022-03-06","kind":"tax_withholding","acquired":false,"shares":263,"price":0.43,"value":113.09,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":313960,"source":{"system":"sec-edgar","filing":"0001104659-22-031514","document":"tm228206-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922031514/tm228206-3_4seq1.xml","form_type":"4"}},{"id":2360173,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-03T00:51:36.000Z","date":"2022-02-28","kind":"tax_withholding","acquired":false,"shares":125,"price":0.45,"value":56.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":314223,"source":{"system":"sec-edgar","filing":"0001104659-22-029492","document":"tm228206-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922029492/tm228206-2_4seq1.xml","form_type":"4"}},{"id":2408151,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-02-08T21:25:48.000Z","date":"2022-02-06","kind":"tax_withholding","acquired":false,"shares":263,"price":0.48,"value":126.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":314348,"source":{"system":"sec-edgar","filing":"0001104659-22-013893","document":"tm221371-13_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922013893/tm221371-13_4seq1.xml","form_type":"4"}},{"id":2419110,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-02-02T01:47:10.000Z","date":"2022-01-31","kind":"tax_withholding","acquired":false,"shares":125,"price":0.48,"value":60.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":314611,"source":{"system":"sec-edgar","filing":"0001104659-22-010535","document":"tm221371-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922010535/tm221371-11_4seq1.xml","form_type":"4"}},{"id":2419109,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-02-02T01:47:10.000Z","date":"2022-01-29","kind":"tax_withholding","acquired":false,"shares":10766,"price":0.45,"value":4844.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":314736,"source":{"system":"sec-edgar","filing":"0001104659-22-010535","document":"tm221371-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922010535/tm221371-11_4seq1.xml","form_type":"4"}},{"id":2419101,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-01T23:37:55.000Z","date":"2022-01-28","kind":"grant","acquired":true,"shares":119900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date."},{"field":"date","element":"transactionDate","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the reporting person's continued employment with the Issuer, the RSUs will vest in equal annual installments over four years with the first installment vesting on January 28, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Subject to the reporting person's continued employment with the Issuer, the RSUs will vest in equal annual installments over four years with the first installment vesting on January 28, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date."}],"balance_after":119900,"derivative":{"underlying":"Ordinary Shares","underlying_shares":119900},"source":{"system":"sec-edgar","filing":"0001104659-22-010487","document":"tm221371-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922010487/tm221371-5_4seq1.xml","form_type":"4"}},{"id":2419100,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Options","published_at":"2022-02-01T23:37:55.000Z","date":"2022-01-28","kind":"grant","acquired":true,"shares":239800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continued employment with Nabriva Therapeutics plc (the \"Issuer\"), the option will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the option will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on a monthly pro-rata basis over the remaining vesting period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right."}],"balance_after":239800,"derivative":{"exercise_price":0.45,"expiration_date":"2032-01-27","underlying":"Ordinary Shares","underlying_shares":239800},"source":{"system":"sec-edgar","filing":"0001104659-22-010487","document":"tm221371-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922010487/tm221371-5_4seq1.xml","form_type":"4"}},{"id":2438820,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-01-10T21:19:35.000Z","date":"2022-01-06","kind":"tax_withholding","acquired":false,"shares":270,"price":0.58,"value":156.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":325502,"source":{"system":"sec-edgar","filing":"0001104659-22-002736","document":"tm221371-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922002736/tm221371-3_4seq1.xml","form_type":"4"}},{"id":2448495,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-01-04T22:06:40.000Z","date":"2021-12-31","kind":"tax_withholding","acquired":false,"shares":107,"price":0.6,"value":64.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":325772,"source":{"system":"sec-edgar","filing":"0001104659-22-000973","document":"tm221371-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465922000973/tm221371-2_4seq1.xml","form_type":"4"}},{"id":2456976,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-12-30T02:32:18.000Z","date":"2021-12-28","kind":"purchase","acquired":true,"shares":100000,"price":0.5732,"value":57320.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.5685 to $0.5750, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price."}],"balance_after":325879,"source":{"system":"sec-edgar","filing":"0001104659-21-154397","document":"tm2136401-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921154397/tm2136401-2_4seq1.xml","form_type":"4"}},{"id":2480427,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-12-08T22:14:26.000Z","date":"2021-12-06","kind":"tax_withholding","acquired":false,"shares":225,"price":0.72,"value":162.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":225879,"source":{"system":"sec-edgar","filing":"0001104659-21-147690","document":"tm2134408-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921147690/tm2134408-4_4seq1.xml","form_type":"4"}},{"id":2488489,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-12-02T23:31:04.000Z","date":"2021-11-30","kind":"tax_withholding","acquired":false,"shares":107,"price":0.78,"value":83.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":226104,"source":{"system":"sec-edgar","filing":"0001104659-21-145998","document":"tm2134408-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921145998/tm2134408-2_4seq1.xml","form_type":"4"}},{"id":2519476,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-11-09T22:38:42.000Z","date":"2021-11-06","kind":"tax_withholding","acquired":false,"shares":225,"price":1.33,"value":299.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":226211,"source":{"system":"sec-edgar","filing":"0001104659-21-136404","document":"tm2132347-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921136404/tm2132347-2_4seq1.xml","form_type":"4"}},{"id":2530534,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-11-01T23:51:30.000Z","date":"2021-10-31","kind":"tax_withholding","acquired":false,"shares":107,"price":1.15,"value":123.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":226436,"source":{"system":"sec-edgar","filing":"0001104659-21-132492","document":"tm2129004d11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921132492/tm2129004d11_4seq1.xml","form_type":"4"}},{"id":2545393,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-10-08T20:39:59.000Z","date":"2021-10-06","kind":"tax_withholding","acquired":false,"shares":225,"price":1.08,"value":243.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":226543,"source":{"system":"sec-edgar","filing":"0001104659-21-124665","document":"tm2129004-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921124665/tm2129004-8_4seq1.xml","form_type":"4"}},{"id":2551713,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-10-04T20:14:40.000Z","date":"2021-09-30","kind":"tax_withholding","acquired":false,"shares":107,"price":1.19,"value":127.33,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":226768,"source":{"system":"sec-edgar","filing":"0001104659-21-122510","document":"tm2129004-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921122510/tm2129004-5_4seq1.xml","form_type":"4"}},{"id":2569150,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-09-16T00:00:20.000Z","date":"2021-09-14","kind":"purchase","acquired":true,"shares":50000,"price":1.13,"value":56500.0,"ownership":{"direct":true},"balance_after":226875,"source":{"system":"sec-edgar","filing":"0001104659-21-116048","document":"tm2123911-18_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921116048/tm2123911-18_4seq1.xml","form_type":"4"}},{"id":2575818,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-09-08T21:27:25.000Z","date":"2021-09-06","kind":"tax_withholding","acquired":false,"shares":225,"price":1.11,"value":249.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":176875,"source":{"system":"sec-edgar","filing":"0001104659-21-113876","document":"tm2123911d16_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921113876/tm2123911d16_4seq1.xml","form_type":"4"}},{"id":2581412,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-09-02T20:07:56.000Z","date":"2021-08-31","kind":"tax_withholding","acquired":false,"shares":107,"price":1.06,"value":113.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":177100,"source":{"system":"sec-edgar","filing":"0001104659-21-112479","document":"tm2123911-13_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921112479/tm2123911-13_4seq1.xml","form_type":"4"}},{"id":2608343,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-08-10T21:16:23.000Z","date":"2021-08-06","kind":"tax_withholding","acquired":false,"shares":225,"price":1.17,"value":263.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":177207,"source":{"system":"sec-edgar","filing":"0001104659-21-102956","document":"tm2123911-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921102956/tm2123911-11_4seq1.xml","form_type":"4"}},{"id":2617391,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-08-03T20:09:15.000Z","date":"2021-07-31","kind":"tax_withholding","acquired":false,"shares":107,"price":1.1,"value":117.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":177432,"source":{"system":"sec-edgar","filing":"0001104659-21-099448","document":"tm2123911-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921099448/tm2123911-3_4seq1.xml","form_type":"4"}},{"id":2637978,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-07-08T20:11:14.000Z","date":"2021-07-06","kind":"tax_withholding","acquired":false,"shares":225,"price":1.27,"value":285.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":177539,"source":{"system":"sec-edgar","filing":"0001104659-21-090218","document":"tm2121385-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921090218/tm2121385-6_4seq1.xml","form_type":"4"}},{"id":2644216,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-07-02T20:06:52.000Z","date":"2021-06-30","kind":"tax_withholding","acquired":false,"shares":107,"price":1.35,"value":144.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":177764,"source":{"system":"sec-edgar","filing":"0001104659-21-088851","document":"tm2121385-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921088851/tm2121385-3_4seq1.xml","form_type":"4"}},{"id":2655729,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-24T22:01:12.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2022 annual meeting of stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2022 annual meeting of stockholders."}],"balance_after":17500,"derivative":{"exercise_price":1.92,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001610618-21-000055","document":"wf-form4_162457203900984.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000161061821000055/wf-form4_162457203900984.xml","form_type":"4"}},{"id":2655801,"issuer":{"id":116495,"kind":"organization","name":"OTONOMY, INC.","symbol":"OTIC"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-24T17:04:24.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date."}],"balance_after":17500,"derivative":{"exercise_price":2.18,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-21-043076","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493566/000120919121043076/doc4.xml","form_type":"4"}},{"id":2677369,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-06-08T20:10:25.000Z","date":"2021-06-06","kind":"tax_withholding","acquired":false,"shares":225,"price":1.34,"value":301.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":177871,"source":{"system":"sec-edgar","filing":"0001104659-21-078230","document":"tm2118134d10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921078230/tm2118134d10_4seq1.xml","form_type":"4"}},{"id":2686183,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-06-02T20:12:10.000Z","date":"2021-05-31","kind":"tax_withholding","acquired":false,"shares":107,"price":1.38,"value":147.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":178096,"source":{"system":"sec-edgar","filing":"0001104659-21-075737","document":"tm2118134-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921075737/tm2118134-3_4seq1.xml","form_type":"4"}},{"id":2720744,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-05-10T21:53:15.000Z","date":"2021-05-06","kind":"tax_withholding","acquired":false,"shares":225,"price":1.49,"value":335.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":178203,"source":{"system":"sec-edgar","filing":"0001104659-21-064055","document":"tm2115115-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921064055/tm2115115-6_4seq1.xml","form_type":"4"}},{"id":2729859,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-05-04T20:03:31.000Z","date":"2021-04-30","kind":"tax_withholding","acquired":false,"shares":107,"price":1.78,"value":190.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":178428,"source":{"system":"sec-edgar","filing":"0001104659-21-060949","document":"tm2115115-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921060949/tm2115115-1_4seq1.xml","form_type":"4"}},{"id":2752841,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-04-09T01:48:52.000Z","date":"2021-04-06","kind":"tax_withholding","acquired":false,"shares":225,"price":1.73,"value":389.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units on 04/06/2021."}],"balance_after":178535,"source":{"system":"sec-edgar","filing":"0001104659-21-048255","document":"tm2112537-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921048255/tm2112537-3_4seq1.xml","form_type":"4"}},{"id":2752840,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-04-09T01:48:52.000Z","date":"2021-03-06","kind":"tax_withholding","acquired":false,"shares":225,"price":1.79,"value":402.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units on 03/06/2021."}],"balance_after":178760,"source":{"system":"sec-edgar","filing":"0001104659-21-048255","document":"tm2112537-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921048255/tm2112537-3_4seq1.xml","form_type":"4"}},{"id":2752839,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-04-09T01:48:52.000Z","date":"2021-02-06","kind":"tax_withholding","acquired":false,"shares":2695,"price":2.9,"value":7815.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units on 02/06/2021."}],"balance_after":178985,"source":{"system":"sec-edgar","filing":"0001104659-21-048255","document":"tm2112537-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921048255/tm2112537-3_4seq1.xml","form_type":"4"}},{"id":2760904,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-04-02T22:11:20.000Z","date":"2021-03-31","kind":"tax_withholding","acquired":false,"shares":107,"price":1.66,"value":177.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":181680,"source":{"system":"sec-edgar","filing":"0001104659-21-046193","document":"tm2112032-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921046193/tm2112032-2_4seq1.xml","form_type":"4"}},{"id":2819646,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-03-03T00:42:02.000Z","date":"2021-02-28","kind":"tax_withholding","acquired":false,"shares":106,"price":2.39,"value":253.34,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units."}],"balance_after":181787,"source":{"system":"sec-edgar","filing":"0001104659-21-030949","document":"tm218516-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921030949/tm218516-4_4seq1.xml","form_type":"4"}},{"id":2885306,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-02-03T01:01:06.000Z","date":"2021-01-31","kind":"tax_withholding","acquired":false,"shares":125,"price":2.62,"value":327.5,"ownership":{"direct":true},"balance_after":181893,"source":{"system":"sec-edgar","filing":"0001104659-21-011105","document":"tm215099-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921011105/tm215099-4_4seq1.xml","form_type":"4"}},{"id":2885305,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-02-03T01:01:06.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":117500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":182018,"source":{"system":"sec-edgar","filing":"0001104659-21-011105","document":"tm215099-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921011105/tm215099-4_4seq1.xml","form_type":"4"}},{"id":4612831,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-01-05T22:15:03.000Z","date":"2020-12-31","kind":"tax_withholding","acquired":false,"shares":121,"price":2.42,"value":292.82,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of ordinary shares reported on this Form 4 reflects a 1-for-10 reverse stock split effected on December 3, 2020."}],"balance_after":64518,"source":{"system":"sec-edgar","filing":"0001104659-21-001032","document":"tm211621-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465921001032/tm211621-4_4seq1.xml","form_type":"4"}},{"id":2962606,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-02T01:21:53.000Z","date":"2020-11-30","kind":"tax_withholding","acquired":false,"shares":1211,"price":0.427,"value":517.097,"ownership":{"direct":true},"balance_after":646396,"source":{"system":"sec-edgar","filing":"0001104659-20-131222","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465920131222/a4.xml","form_type":"4"}},{"id":2996390,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-11-03T00:07:33.000Z","date":"2020-10-31","kind":"tax_withholding","acquired":false,"shares":1211,"price":0.4955,"value":600.0505,"ownership":{"direct":true},"balance_after":647607,"source":{"system":"sec-edgar","filing":"0001104659-20-120641","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465920120641/a4.xml","form_type":"4"}},{"id":3018448,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-10-01T20:32:05.000Z","date":"2020-09-30","kind":"tax_withholding","acquired":false,"shares":1211,"price":0.533,"value":645.463,"ownership":{"direct":true},"balance_after":648818,"source":{"system":"sec-edgar","filing":"0001104659-20-111079","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465920111079/a4.xml","form_type":"4"}},{"id":3040944,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-02T21:15:01.000Z","date":"2020-08-31","kind":"tax_withholding","acquired":false,"shares":1211,"price":0.6194,"value":750.0934,"ownership":{"direct":true},"balance_after":650029,"source":{"system":"sec-edgar","filing":"0001104659-20-101905","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465920101905/a4.xml","form_type":"4"}},{"id":3069378,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-08-04T20:08:03.000Z","date":"2020-07-31","kind":"tax_withholding","acquired":false,"shares":1211,"price":0.76,"value":920.36,"ownership":{"direct":true},"balance_after":651240,"source":{"system":"sec-edgar","filing":"0001104659-20-090281","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465920090281/a4.xml","form_type":"4"}},{"id":3091452,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-07-02T20:06:55.000Z","date":"2020-06-30","kind":"tax_withholding","acquired":false,"shares":1211,"price":0.6746,"value":816.9406,"ownership":{"direct":true},"balance_after":652451,"source":{"system":"sec-edgar","filing":"0001104659-20-080540","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465920080540/a4.xml","form_type":"4"}},{"id":3099684,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2020-06-25T23:04:45.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2021 annual meeting of stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2021 annual meeting of stockholders."}],"balance_after":17500,"derivative":{"exercise_price":3.97,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001140361-20-014785","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000114036120014785/form4.xml","form_type":"4"}},{"id":3099747,"issuer":{"id":116495,"kind":"organization","name":"OTONOMY, INC.","symbol":"OTIC"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-25T17:08:26.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date."}],"balance_after":17500,"derivative":{"exercise_price":3.56,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-20-038946","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493566/000120919120038946/doc4.xml","form_type":"4"}},{"id":3123722,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-06-03T10:07:05.000Z","date":"2020-05-31","kind":"tax_withholding","acquired":false,"shares":1211,"price":1.14,"value":1380.54,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The total reported in Column 5 includes 6,187 shares acquired under Nabriva Therapeutics plc's 2018 Employee Stock Purchase Plan (\"ESPP\") on May 29, 2020."}],"balance_after":653662,"source":{"system":"sec-edgar","filing":"0001104659-20-069182","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465920069182/a4.xml","form_type":"4"}},{"id":3136986,"issuer":{"id":5169,"kind":"organization","name":"COLLEGIUM PHARMACEUTICAL, INC"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-05-22T20:22:11.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":8095,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable on May 20, 2021, subject to the director's continued service with the issuer."}],"balance_after":8095,"derivative":{"exercise_price":22.05,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":8095},"source":{"system":"sec-edgar","filing":"0001192482-20-000363","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000119248220000363/edgar.xml","form_type":"4"}},{"id":3136985,"issuer":{"id":5169,"kind":"organization","name":"COLLEGIUM PHARMACEUTICAL, INC"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-22T20:22:11.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":4047,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2021, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock."}],"balance_after":11007,"source":{"system":"sec-edgar","filing":"0001192482-20-000363","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000119248220000363/edgar.xml","form_type":"4"}},{"id":3163511,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-05-04T22:31:55.000Z","date":"2020-04-30","kind":"tax_withholding","acquired":false,"shares":1211,"price":0.5483,"value":663.9913,"ownership":{"direct":true},"balance_after":648686,"source":{"system":"sec-edgar","filing":"0001104659-20-056350","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465920056350/a4.xml","form_type":"4"}},{"id":3186241,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-04-02T21:48:17.000Z","date":"2020-03-31","kind":"tax_withholding","acquired":false,"shares":1211,"price":0.575,"value":696.325,"ownership":{"direct":true},"balance_after":649897,"source":{"system":"sec-edgar","filing":"0001104659-20-042579","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465920042579/a4.xml","form_type":"4"}},{"id":3231746,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-03-04T02:32:47.000Z","date":"2020-02-28","kind":"tax_withholding","acquired":false,"shares":1211,"price":1.35,"value":1634.85,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The total reported in Column 5 includes 5,759 shares acquired under Nabriva Therapeutics plc's 2018 Employee Stock Purchase Plan (\"ESPP\") on October 31, 2019."}],"balance_after":651108,"source":{"system":"sec-edgar","filing":"0001104659-20-028852","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465920028852/a4.xml","form_type":"4"}},{"id":3281894,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2020-02-11T01:27:00.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":687500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"The option was granted on February 6, 2020, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option will vest over a four-year period beginning on February 6, 2020. Twenty-five percent (25%) of the option will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on a monthly pro-rata basis over the remaining vesting period."}],"balance_after":687500,"derivative":{"exercise_price":1.35,"expiration_date":"2030-02-05","underlying":"Ordinary Shares","underlying_shares":687500},"source":{"system":"sec-edgar","filing":"0001104659-20-015172","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465920015172/a4.xml","form_type":"4"}},{"id":3281893,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-02-11T01:27:00.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":343800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the reporting person's receipt of a grant of 343,800 restricted stock units. The total reported in Column 5 includes the 343,800 newly awarded restricted stock units."}],"balance_after":646560,"source":{"system":"sec-edgar","filing":"0001104659-20-015172","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465920015172/a4.xml","form_type":"4"}},{"id":3291250,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-02-05T01:55:25.000Z","date":"2020-01-31","kind":"tax_withholding","acquired":false,"shares":16276,"price":1.35,"value":21972.6,"ownership":{"direct":true},"balance_after":302760,"source":{"system":"sec-edgar","filing":"0001104659-20-010897","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465920010897/a4.xml","form_type":"4"}},{"id":3427257,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":45189,"kind":"person","name":"Schroeder Theodore R","position":1,"cik":"0001378690","reported_name":"Schroeder Theodore R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-08-28T20:01:58.000Z","date":"2019-08-27","kind":"purchase","acquired":true,"shares":50000,"price":1.79,"value":89500.0,"ownership":{"direct":false,"nature":"Schroeder Living Trust"},"balance_after":117489,"source":{"system":"sec-edgar","filing":"0001104659-19-047723","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378690/000110465919047723/a4.xml","form_type":"4"}}],"next_cursor":"2019-08-28T20:01:58.000000Z,3427257"}